• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment

expresspharmaMay 07, 2021

Tag: NATCO , Baricitinib , COVID-19 , Remdesivir

Natco Pharma has received emergency-use approval for Baricitinib tablets – 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib, in combination with Remdesivir, is used for the treatment of COVID-19-positive patients.

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment

Natco will be requesting a compulsory license based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make it available to suffering patients across India.

Previous:Centre has so far provided over 16.54 crore vaccine doses to states/UTs for free

Next:Pfizer in talks with India over expedited approval for COVID-19 vaccine

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Baricitinib

Baricitinib
BARICITINIB

BARICITINIB
Baricitinib

Baricitinib
Remdesivir N-4 intermediate

Remdesivir N-4 intermediate
Remdesivir

Remdesivir
Baricitinib

Baricitinib

Remdesivir

Remdesivir
Remdesivir

Remdesivir
SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)
Remdesivir

Remdesivir

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service